The Liechtenstein-based drug delivery company Pantec Biosolutions has expanded its scientific advisory board to include Professor Rox Anderson, Dr Jean-Luc Levy and Professor Robert Strohal. Dr Anderson is a professor at Harvard Medical School, an adjunct professor at Massachusetts Institute of Technology and director of the Wellman Center for Photomedicine at Massachusetts General Hospital; Dr Levy has more than 20 years' experience in the field of health technology, specifically for laser application in dermatology and cosmetology; and Dr Strohal is associate professor and head of the department of dermatology and venerology at the Federal University Teaching Hospital Feldkirch, Austria.
Pantec Biosolutions expands scientific advisory board
Listen to this article
The Liechtenstein-based drug delivery company Pantec Biosolutions has expanded its scientific advisory board to include Professor Rox Anderson, Dr Jean-Luc Levy and Professor Robert Strohal. Dr Anderson is a professor at Harvard Medical School, an adjunct professor at Massachusetts Institute of Technology and director of the Wellman Center for Photomedicine at Massachusetts General Hospital; Dr Levy has more than 20 years' experience in the field of health technology, specifically for laser application in dermatology and cosmetology; and Dr Strohal is associate professor and head of the department of dermatology and venerology at the Federal University Teaching Hospital Feldkirch, Austria.
Keep up with the top pharma business news of the week. On the go.
More from Business
• By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
• By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains